FCMV

Foresite Capital Management VI Portfolio holdings

AUM $331M
1-Year Est. Return 90.48%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+90.48%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$331M
AUM Growth
+$72M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
15
New
Increased
Reduced
Closed

Top Buys

1
+$18.6M
2
+$14M
3
+$13M
4
VSTM icon
Verastem
VSTM
+$4.63M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$1.27M

Top Sells

1
+$11.6M
2
+$2.76M
3
+$1.74M
4
CASI
CASI Pharmaceuticals
CASI
+$1.63M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$5.32B
$92.2M 27.88%
2,221,474
RAPT
2
DELISTED
RAPT Therapeutics
RAPT
$52.9M 16%
1,562,500
ALMS
3
Alumis Inc
ALMS
$3.12B
$41.5M 12.53%
4,247,670
CNTA
4
Centessa Pharmaceuticals
CNTA
$4.02B
$34.1M 10.31%
1,364,019
+50,000
VSTM icon
5
Verastem
VSTM
$440M
$24.2M 7.32%
3,135,120
+520,000
DNLI icon
6
Denali Therapeutics
DNLI
$3.28B
$16.5M 4.99%
1,000,000
NTRA icon
7
Natera
NTRA
$27B
$15.4M 4.66%
+67,356
AGIO icon
8
Agios Pharmaceuticals
AGIO
$1.62B
$14.4M 4.36%
+530,000
KYMR icon
9
Kymera Therapeutics
KYMR
$6.33B
$11.4M 3.44%
146,332
ATAI icon
10
AtaiBeckley Inc
ATAI
$1.39B
$11.2M 3.4%
+2,750,000
CRVS icon
11
Corvus Pharmaceuticals
CRVS
$1.34B
$10.6M 3.21%
1,381,233
-350,000
HNGE
12
Hinge Health
HNGE
$3.5B
$6.27M 1.9%
135,000
AKRO
13
DELISTED
Akero Therapeutics
AKRO
– –
-244,900
CASI
14
DELISTED
CASI Pharmaceuticals
CASI
– –
-979,956
RNAM
15
DELISTED
Avidity Biosciences
RNAM
– –
-40,000